ClinicalTrials.gg
CompletedNCT03430648SYNERGYUpdated Aug 31, 2023

Is Tau Protein Linked to Mobility Function?

An observational study in Alzheimer Disease and Physical Activity, sponsored by Wake Forest University Health Sciences. Completed at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2023-08-31.

Sponsored by Wake Forest University Health Sciences · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
37
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 16 studies in Alzheimer Disease by Wake Forest University Health Sciences — 3 open to participants now, 4 under way, none of them phase 3. Alzheimer Disease · Wake Forest University Health Sciences.

Started
2017
the only one that year
Observational
5 of 16
2 open now
Registered
8th of 16
by date

Among the 16 studies in Alzheimer Disease by Wake Forest University Health Sciences, this one is the only one that started in 2017, is one of 5 observational ones, and was the 8th registered.

Alzheimer Disease

3,965 studies on the registry are indexed under Alzheimer Disease; 926 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

3 of the 16 studies in Alzheimer Disease by Wake Forest University Health Sciences are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 641 Alzheimer Disease studies recruiting now, 283 (44%) set no upper age limit and 54 (8%) stop at 75 or younger; 34 take children under 18; 283 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Alzheimer Disease by Wake Forest University Health Sciences, or all of them as a file.
02

Study summary

This project will provide new data to address an important question linking Alzheimer's disease neuropathology to physical disability.

Read the detailed description

Impaired mobility is strongly linked to cognitive function and vice versa. Cognitive functions are strongly associated with mobility function, most commonly assessed using gait speed. In the Health ABC Study, Digit Symbol Substitution Test (DSST) and Modified Mini Mental Status (3MS) scores were significantly associated with gait speed and gait speed decline. Poor lower extremity performance predicts faster age-related cognitive decline and increased incidence of mild cognitive impairment (MCI) and dementia. This study will explore the role of tau protein as the neuropathologic basis for these associations.

Brain imaging markers may be the link between cognitive measures and gait. White matter disease is commonly measured by quantifying white matter (WM) lesion load, which is associated with small vessel ischemic disease. More subtle microstructural changes can be observed by calculating fractional anisotropy (FA) from diffusion tensor imaging (DTI). Aging is accompanied by changes in cortical volume, white matter microstructure and an increased prevalence of WM lesions. WM lesions have been strongly implicated in declining physical function. These brain changes are associated with impaired balance, slower movement speeds, slower chair stand times and increased falls risk.Recently, Aâ accumulation in the brain has also been linked to slow gait. This finding suggests a pathologic mechanism linking Alzheimer s disease processes to gait impairments. However, Aâ accumulation itself may not be the critical neuropathic change. In recent studies of Aâ42 and phosphorylated tau protein in cerebral spinal fluid, it has been found that low Aâ42 levels themselves are not associated with impaired cognition, but that elevated tau levels are also required. If the process of cognitive impairment parallels the process of gait impairment, it might be that tau levels are more important correlates of gait changes. To the investigators' knowledge the relationship between CSF tau levels and mobility has never been explored. PET ligands for brain tau have recently become available, but the relationship between brain tau accumulation and gait has yet to be determined. In this study, investigators will relate gait characteristics to CSF Aâ42 and phosphorylated tau levels, and perform brain PET imaging in a subset to related tau protein accumulation to gait characteristics for the first time. Both mobility impairment and Alzheimers disease (AD) occur in the context of the aging vascular system. Over the past 15 years, it has been recognized that abnormalities of thoracic aortic stiffness are associated with the development of abnormalities in small vessels supplying the brain and kidneys. As the aorta stiffens, the propagation speed of the systolic flow wave increases through the aortic lumen. (Stiffness within the thoracic aorta can be accomplished through measurement of aortic pulse wave velocity.) In hypertensive patients, aortic archway pulse wave velocity has been associated with increases in left ventricular mass as well as lacunar brain infarcts independent of age, sex, and the duration of hypertension. In the Multi-Ethnic Dallas Heart Study aortic arch pulse wave velocity is an independent predictor of white matter hyper-intensities. In those with diabetes, increasing aortic stiffness contributes to the development of small vessel microvascular dysfunction which is associated with deep white matter atrophy as well as cognitive decline. Recently, a stiffness mismatch between the thoracic aorta and small vessels within the cerebral microcirculation has been described. This mismatch impacts microvascular pulsatility and appears to diminish diffusion anisotrophy between the cerebral spinal fluid and the CNS microcirculation. This observation may contribute to retained amyloid type protein in those with AD.

03

Conditions studied

  • Alzheimer Disease
  • Physical Activity

Keywords

  • Tau protein
  • PET imaging
  • Alzheimer's disease
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Investigators plan to recruit a total of 60 people age 50 and older from the Wake Forest Alzheimer's Disease Research Center's Clinical Core group.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 50+ years of age and participated in the Wake Forest Alzheimer's Disease Core Center study
  • Willing to provide
  • Not dependent on a walker

Exclusion criteria

Exclusion Criteria:

  • Recent cardiac event in the last 6 months
  • Uncontrolled hypertension (BP >200/110 mmHg)
  • Neurological (e.g., Parkinson's) or hematological disease
  • Participants with a knee replacement in last 6 months
  • Participants with recent eye surgery in last 6 months
  • Severe musculoskeletal impairment (e.g., sciatica, fibromyalgia, severe leg/back pain)
  • If willing to get an MRI, must not have indwelling metal-contraining prosthesis, pacemaker or defibrillator, history of welding, permanent make up or head/neck tattoo, or any other to MRI
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
37 participants (actual)
Patient registry
No

Groups and cohorts

  • Cognitively and metabolically normal

    This group has been defined as being cognitively and metabolically normal.

  • Cognitively normal with prediabetes

    This group has been defined as being cognitively normal but showing signs of prediabetes.

  • Persons with Mild Cognitive Impairment

    This group has been defined as being mildly cognitively impaired.

  • Persons with early Alzheimer's disase

    This group has been defined as having early Alzheimer's disease.

06

What researchers measure

Primary outcomes

  1. Association between CSF total and phosphorylated tau levels and gait speed

    This will be done using the 400m walk test.

    Time frame: Baseline

  2. Association between CSF total and phosphorylated tau levels and gait variability

    This will be done using the gaitrite mat.

    Time frame: Baseline

  3. Association between CSF total and phosphorylated tau levels and standing balance.

    This will be done using the AMTI force plate.

    Time frame: Baseline

Secondary outcomes

  1. Examine the association between Digit Symbol Substitution Test and gait speed

    Time frame: Baseline

07

Study locations

1 site
  • Wake Forest Baptist Medical Center
    Winston-Salem, North Carolina 27157, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Sep 2021, 48 months.

Of 364 non-industry observational studies under Alzheimer Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 203. This study's 48 months is below that.

Counting every sponsor, half of 405 studies reached it within 67 months; a quarter within 35 and three quarters within 171.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2018
First posted
Feb 13, 2018
StartActual
Sep 7, 2017
Primary completionActual
Sep 27, 2021
CompletionActual
Sep 27, 2021
Last update
Aug 31, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03430648
Responsible party
Sponsor
First posted
Feb 13, 2018
Start date
Sep 7, 2017
Primary completion
Sep 27, 2021
Completion
Sep 27, 2021
Last update
Aug 31, 2023

Study contacts

Stephen Kritchevsky, PhD
principal investigator · Wake Forest University Health Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion